Clinical trials: Subcutaneous Fat
Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS), Human Immunodeficiency Virus Infections
An Efficacy and Safety Trial of Serostim® in the Maintenance of the Treatment Effect Obtained During the Study of Serostim® in Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome
This is an open-label, multi-center, randomized, parallel-group, maintenance trial of Serostim® in subjects who have completed a prior Serostim® Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS) trial…
- Trial name
- NCT00294918
- Testing
- Serostim®
- Volunteers
- 142 people
- Sponsor
- EMD Serono
Moderate or Severe Submental Fullness
Phase 1-2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat
To evaluate the safety and potential efficacy of deoxycholic acid injection compared to placebo for the reduction of submental fat (fat below the chin).
- Trial name
- ATX-101 (NCT00618722)
- Testing
- Deoxycholic Acid Injection
- Where
- 6 sites in Australia, Canada and 1 more
- Volunteers
- 85 people
- Sponsor
- Kythera Biopharmaceuticals
Plaque Psoriasis
Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis Patients
This study provided a comparison of secukinumab to placebo with respect to skin inflammation as measured by skin exams in comparison to skin biopsies, adipose tissue and blood sample analyses.
- Trial name
- ObePso-S (NCT03055494)
- Testing
- Secukinumab
- Where
- 15 sites in United States
- Volunteers
- 102 people
- Sponsor
- Novartis Pharmaceuticals
Subcutaneous Fat
A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 2)
The Stage 2 of this phase 2 study will be a randomized, single-blind, placebo-controlled, parallel, and multiple-dose study to assess the efficacy, safety, and subject satisfaction of CBL-514.
- Trial name
- NCT04897412
- Testing
- CBL-514 Injection
- Where
- 5 sites in United States, Australia
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
Subcutaneous Fat
A Phase 1 Study to Evaluate the Safety and Tolerability of CBL-514 Injection on Convexity or Fullness of Abdominal Subcutaneous Fat in Healthy Volunteers
The Phase 1 component of the study is a double-blind, placebo-controlled, single ascending dose (SAD) design intended to assess the safety, tolerability, and PK of CBL-514. The SAD part will involve 9 proposed dosing cohorts.
- Trial name
- NCT04699669
- Testing
- CBL-514
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
Obesity
Technical Validation of Lunar iDXA Visceral Fat Tool
The goal of this project is to compare visceral fat measurements derived from Lunar iDXA total body scans and from Computed Tomography (CT) scans of the abdominal region for a Chinese population.
- Trial name
- NCT01110161
- Testing
- Visceral fat mass measurement
- Where
- China
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Non-Surgical Fat Reduction
A Study to Assess Non-Invasive Subcutaneous Fat Reduction in the Submental, Inner Thigh and Back/Bra Areas With the CoolSculpting Elite System
The primary objective of this protocol is the continued collection of data specific to the submental, inner thigh and back/bra body areas with CoolSculpting Elite.
- Trial name
- NCT07122583
- Testing
- CoolSculpting Elite System
- Where
- United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- AbbVie
Submental Fat
Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Submental Subcutaneous Fat
Study LIPO-202-CL-31 is a multi center, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of two different doses of LIPO-202 versus placebo on submental bulging due to subcutaneous fat.
- Trial name
- NCT03005717
- Testing
- LIPO-202
- Where
- 11 sites in United States
- Volunteers
- 162 people
- Sponsor
- Neothetics, Inc